Evidence map›Paper›PMID 35860600›Full record

ArticlePNAS nexus2022

SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes.

Colin Pawlowski, Eli Silvert, John C O'Horo, Patrick J Lenehan, Doug Challener, Esteban Gnass, Karthik Murugadoss, Jason Ross, Leigh Speicher, Holly Geyer and 3 more

Open access · goldAbstract read
In one paragraph

Article in PNAS nexus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Clinical Evaluation of Xpert Xpress CoV-2/Flu/RSVDiagnostics (Basel, Switzerland) · 2024
    Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Colin Pawlowskinference, Cambridge, MA 02139, USA.ORCID https://orcid.org/0000-0003-2781-7507
Eli Silvertnference, Cambridge, MA 02139, USA.
John C O'HoroMayo Clinic, Rochester, MN 55902, USA.ORCID https://orcid.org/0000-0002-0880-4498
Patrick J Lenehannference, Cambridge, MA 02139, USA.ORCID https://orcid.org/0000-0002-1950-9179
Doug ChallenerMayo Clinic, Rochester, MN 55902, USA.ORCID https://orcid.org/0000-0002-6964-9639
Esteban Gnassnference, Cambridge, MA 02139, USA.
Karthik Murugadossnference, Cambridge, MA 02139, USA.
Jason Rossnference, Rochester, MN 55902, USA.ORCID https://orcid.org/0000-0002-4594-2080
Leigh SpeicherMayo Clinic, Jacksonville, FL 32224, USA.
Holly GeyerMayo Clinic, Scottsdale, AZ 85259, USA.
A J Venkatakrishnannference, Cambridge, MA 02139, USA.
Andrew D BadleyMayo Clinic, Rochester, MN 55902, USA.
Venky Soundararajannference, Cambridge, MA 02139, USA.ORCID https://orcid.org/0000-0001-7434-9211
Nference (United States) · USMayo Clinic in Arizona · USWinnMed · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Prime shock and kill for HIV erradicationR01AI110173 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2014 to 2024
$6.9M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.R01AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2015 to 2019
$2.5M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistenceR56AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2021 to 2021
$607k
NIAID NIH HHS R01 AI110173NIAID NIH HHS R01 AI120698NIAID NIH HHS R56 AI120698NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Case reports of patients infected with COVID-19 and influenza virus ("flurona") have raised questions around the prevalence and severity of coinfection. Using data from

Indexed as

Co-infectionCOVID-19FluFluronaInfluenzaSARS-CoV-2

Identifiers

PMID35860600
PMCPMC9291226
OpenAlexW4283791975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.